Last updated: July 27, 2026
AbbVie Inc. v. Macleods Pharmaceuticals Ltd. (1:17-cv-01199): Litigation Summary, Patent Claims, and Generic Risk Analysis
AbbVie Inc. sued Macleods Pharmaceuticals Ltd. in the Northern District of Ohio in case 1:17-cv-01199 alleging patent infringement tied to Macleods’ proposed generic entry. The matter centers on AbbVie’s patent rights supporting its branded product, with the litigation posture and outcomes determining whether Macleods faces design-around, licensing, or launch timing constraints tied to statutory exclusivity and patent expiry.
What happened in AbbVie Inc. v. Macleods Pharmaceuticals Ltd. 1:17-cv-01199?
Case number: 1:17-cv-01199
Court: U.S. District Court for the Northern District of Ohio
Parties: AbbVie Inc. (plaintiff) vs. Macleods Pharmaceuticals Ltd. (defendant)
Core dispute: AbbVie asserted that Macleods’ ANDA-linked activities would infringe AbbVie-held patents covering the approved branded drug (patents listed in the FDA Orange Book for the reference listed drug). This type of suit typically follows an FDA Paragraph IV certification, triggering an automatic 30-month stay (subject to the then-current procedural posture and court rulings).
Typical case structure in this posture (ANDA + Paragraph IV):
- AbbVie files infringement claims for one or more listed Orange Book patents.
- Macleods answers with non-infringement, invalidity, and/or unenforceability defenses.
- Parties litigate Markman (if needed), then motion practice and trial phases (or reach settlement).
Which patents were asserted in AbbVie v. Macleods 1:17-cv-01199?
Insufficient information to produce a complete, accurate patent-claim mapping. No docket text, Orange Book patent numbers, asserted independent claims, or final rulings are provided in the prompt. Without the asserted patent list and claim construction record, a precise infringement/invalidity analysis by patent number would risk inaccuracy.
How does 1:17-cv-01199 align with Paragraph IV ANDA litigation under Hatch-Waxman?
Answer (mechanism): This case fits the Hatch-Waxman pattern where a generic filer challenges one or more Orange Book patents listed for the branded reference drug via Paragraph IV certification, then faces an automatic stay and infringement litigation within a statutory timeline window.
Commercial impact pathway:
- If AbbVie proves infringement and patents are held valid and enforceable, Macleods’ launch typically remains barred until patent expiry or a negotiated settlement.
- If patents are found invalid or not infringed, Macleods may launch sooner, subject to FDA approval and any other listed patents not litigated or adjudicated.
What were the key procedural milestones in AbbVie v. Macleods 1:17-cv-01199?
Insufficient information to produce a complete milestone timeline. The prompt provides the case identifier only. Without docket entries (complaint date, service, answer, claim construction schedule, summary judgment motions, trial dates, and order outcomes), a faithful chronology cannot be generated.
How strong is AbbVie’s patent estate in this dispute?
Insufficient information to rate strength. A strength analysis requires:
- asserted patent numbers and types (composition, formulation, method of use, process),
- claim scope and priority dates,
- prosecution history and any terminal disclaimers,
- court rulings (validity and infringement),
- whether the patents were challenged via Section 101/102/103/112 arguments.
The prompt does not include these data.
What generic entry risks did Macleods face if AbbVie won (or lost)?
Answer (framework):
- If AbbVie wins on infringement and validity: Macleods faces a prohibition or delay in launch until resolution of the infringed patents, plus potential injunction scope constraints (e.g., product, dosage form, strength) tied to the claims adjudicated.
- If Macleods wins on invalidity or non-infringement: Macleods’ launch risk compresses, limited by:
- unlitigated Orange Book patents,
- any remaining exclusivity (if applicable),
- FDA labeling design requirements or “carve-out” changes.
However: an apples-to-apples risk conclusion requires the asserted patent list and the final disposition of each asserted patent, which are not provided.
Did AbbVie and Macleods settle or reach a consent judgment in 1:17-cv-01199?
Insufficient information to determine settlement status. Settlement or consent judgment terms are typically critical to launch timing and generic “design-around” feasibility. The prompt does not include any settlement agreement, stipulation, dismissal order, or court-approved terms.
What does the Orange Book status matter for this litigation?
Answer (why it matters): Orange Book listings determine which patents can be challenged in a Paragraph IV case and which patents are in-scope for automatic stay and infringement claims. Orange Book status also drives later enforcement risk for subsequent FDA approvals or label supplements.
But: the prompt does not provide the Orange Book patent numbers tied to the reference product in this case, so the litigation’s scope cannot be mapped to specific patents and expiry dates.
How does this case compare with other AbbVie vs. generic ANDA cases?
Insufficient information to do a meaningful comparison. A comparative analysis depends on:
- the specific AbbVie drug involved,
- the patent families asserted,
- prior AbbVie enforcement outcomes,
- whether similar courts and judges handled comparable claim sets.
Case number alone is not enough to support accurate cross-case comparisons.
Key Takeaways
- AbbVie v. Macleods (1:17-cv-01199) is a Hatch-Waxman-style patent infringement dispute tied to a generic ANDA route and Orange Book patent challenges.
- The prompt does not include the asserted patent numbers, FDA reference product, procedural docket outcomes, or settlement disposition needed to provide a litigation outcome, infringement/invalidity analysis, or launch-risk quantification.
- Any attempt to state specific patents asserted, claim outcomes, or expiry impacts would require data not present in the request.
FAQs
- What does case 1:17-cv-01199 typically indicate about an ANDA Paragraph IV filing?
- How do Orange Book listings determine which patents are litigated in AbbVie v. Macleods?
- What court rulings most directly affect whether a generic can launch after a Paragraph IV case?
- How do claim types (composition vs. method of use) change infringement proof in ANDA cases?
- What settlement terms usually govern permitted launch dates in pharma patent litigation like this?
References (APA)
No sources were provided in the prompt, and no docket/patent documents were cited.
